Hem › Sickelcellssjukdom › Alabama
Kliniska studier för Sickelcellssjukdom i Alabama
16 studier för Sickelcellssjukdom söker deltagare vid platser i Alabama.
Städer i Alabama
Officiell studietext (engelska)
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- University Of Alabama, Birmingham
RekryterarFas 3
Ålder 12 till 100 · Alla kön · Uppdaterad 28 sep. 2026 · NCT06439082A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- University of Alabama at Birmingham, Birmingham
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 23 sep. 2026 · NCT07187973A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Uni of Alabama at Birmingham, Birmingham
- Univer South Alabama Ped/Onc, Mobile
RekryterarFas 3
Ålder 12 och äldre · Alla kön · Uppdaterad 17 sep. 2026 · NCT06612268A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- University of Alabama Birmingham, Birmingham
RekryterarFas 1/2Friska volontärer välkomna
Ålder 12 till 55 · Alla kön · Uppdaterad 9 sep. 2026 · NCT06546670SCD Stem Cell Mobilization and Apheresis Using Motixafortide
- University of Alabama at Birmingham, Birmingham
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 8 sep. 2026 · NCT06442761A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
- University of Alabama at Birmingham, Birmingham
RekryterarFas 1/2Friska volontärer välkomna
Ålder 18 och äldre · Alla kön · Uppdaterad 18 aug. 2026 · NCT06481306A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- AMR Clinical, Mobile
RekryterarFas 2/3
Ålder 12 och äldre · Alla kön · Uppdaterad 18 aug. 2026 · NCT05431088The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- University of Alabama at Birmingham- Site Number : 8400003, Birmingham
RekryterarFas 3
Ålder 10 till 65 · Alla kön · Uppdaterad 29 juli 2026 · NCT06975865Early Life Exposures Among Children With Sickle Cell Disease
- University of Alabama at Birmingham, Birmingham
Rekryterar
Ålder 18 till 50 · Kvinnor · Uppdaterad 15 juli 2026 · NCT05377372Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
- University Of Alabama, Birmingham
RekryterarFas 4
6 Months – 100 Years · Alla kön · Uppdaterad 8 juni 2026 · NCT04657822Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
- Children's of Alabama (MRD-HCT), Birmingham
- Children's of Alabama (NT-DMT), Birmingham
RekryterarObservationsstudie
Ålder 3 till 20 · Alla kön · Uppdaterad 4 juni 2026 · NCT06941389Cognitive Remediation Intervention to Prepare for Transition of Care
- University of Alabama at Birmingham, Birmingham
RekryterarFas 2
Ålder 10 till 18 · Alla kön · Uppdaterad 27 feb. 2026 · NCT05336201A Long-term Follow-up Study in Patients Who Received BEAM-101
- University of Alabama at Birmingham, Birmingham
RekryterarObservationsstudie
Ålder 14 till 37 · Alla kön · Uppdaterad 28 jan. 2026 · NCT07373639Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
- University of South Alabama Medical Center, Mobile
Rekryterar
Ålder 16 till 30 · Alla kön · Uppdaterad 7 jan. 2026 · NCT06374238HPC Offered for PRESERVE Expansion
- University of Alabama, Birmingham, Birmingham
RekryterarObservationsstudie
Ålder 12 till 80 · Alla kön · Uppdaterad 28 aug. 2025 · NCT07145411Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
- University of Alabama, Birmingham (UAB), Birmingham
RekryterarObservationsstudie
Ålder 18 och äldre · Alla kön · Uppdaterad 22 juni 2025 · NCT06385886Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.